Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May-Jun;28(3):176-182.
doi: 10.1097/PPO.0000000000000599.

Update on Pregnancy Following Breast Cancer Diagnosis and Treatment

Marta Perachino, Francesca Poggio  1 , Luca Arecco, Eva Blondeaux  2 , Stefano Spinaci  3 , Camilla Marrocco  2 , Alessia Levaggi  2 , Matteo Lambertini
Affiliations
Review

Update on Pregnancy Following Breast Cancer Diagnosis and Treatment

Marta Perachino et al. Cancer J. 2022 May-Jun.

Abstract

Survivorship has become a crucial component in breast cancer care. For women who have not completed their family planning, conceiving at the end of anticancer treatments should not be discouraged but might be challenging. Oncofertility counseling should be offered at the time of diagnosis to all patients, in order to inform them about the potential treatment-induced gonadotoxicity as well as the available strategies for fertility preservation, thus allowing to increase the chances of a future pregnancy. This article reports an updated overview on the current state of the art on pregnancy in women with prior breast cancer diagnosis and treatment, with a main focus on the issues faced by patients with history of hormone receptor-positive disease and BRCA carriers.

Trial registration: ClinicalTrials.gov NCT03155997 NCT00833963 NCT02032823 NCT02308085.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest and Source of Funding: F.P. received honoraria from Eli Lilly, Novartis, and Pfizer. M.L. had advisory role for Roche, Lilly, Novartis, Astrazeneca, MSD, Exact Sciences, Seagen, Gilead, and Pfizer and received speaker honoraria from Roche, Lilly, Novartis, Pfizer, Sandoz, Libbs, Knight, and Takeda outside the submitted work. M.L. acknowledges the Italian Association for Cancer Research (“Associazione Italiana per la Ricerca sul Cancro,” AIRC; MFAG 2020 ID 24698) and the Italian Ministry of Health (5 × 1000 funds 2017) for supporting his research in the field of breast cancer in young women and oncofertility. For the remaining authors, none were declared.

References

    1. Fidler MM, Gupta S, Soerjomataram I, et al. Cancer incidence and mortality among young adults aged 20–39 years worldwide in 2012: a population-based study. Lancet Oncol. 2017;18:1579–1589.
    1. Azim HA, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014;16:427.
    1. Partridge AH, Hughes ME, Warner ET, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 2016;34:3308–3314.
    1. Poggio F, Lambertini M, Bighin C, et al. Management of young women with early breast cancer. ESMO Open. 2018;3:e000458.
    1. Poorvu PD, Hu J, Zheng Y, et al. Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer. Npj Breast Cancer. 2021;7:99.

Associated data